Skip to content

EPRX

Eupraxia Pharmaceuticals Inc.

NASDAQ · Healthcare · Biotechnology · CA

$8.40
+12.00%
Ask drillr
Institutional positioning

13F filings over the trailing two quarters

New 22Increased 21Reduced 6Sold out 54
FilerActionSharesFiled
BEUTEL, GOODMAN & CO LTD.Reduced3,666,465May 15, 2026
AFFINITY ASSET ADVISORS, LLCIncreased1,589,005May 14, 2026
BALYASNY ASSET MANAGEMENT L.P.Unchanged1,350,000May 15, 2026
VIVO CAPITAL, LLCUnchanged1,350,000May 20, 2026
SCOTIA CAPITAL INC.Increased1,342,178May 13, 2026
IKARIAN CAPITAL, LLCIncreased1,214,741May 15, 2026
GREAT POINT PARTNERS LLCUnchanged1,200,000May 15, 2026
POINT72 ASSET MANAGEMENT, L.P.Increased967,575May 15, 2026
UBS GROUP AGIncreased762,635May 5, 2026
REDMILE GROUP, LLCNew Position700,000May 15, 2026
RUBRIC CAPITAL MANAGEMENT LPNew Position691,170May 15, 2026
Squadron Capital Management LLCIncreased680,000May 15, 2026
ALLY BRIDGE GROUP (NY) LLCIncreased660,375May 18, 2026
AMERIPRISE FINANCIAL INCNew Position649,074Jul 17, 2026
PFM HEALTH SCIENCES, LPNew Position540,871May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings